APA (7th ed.) Citation

Patil, S. G., Linge, A., Hiepe, H., Grosser, M., Lohaus, F., Gudziol, V., . . . Löck, S. (2022). A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT. Cancers, 14(12), . https://doi.org/10.3390/cancers14123031

Chicago Style (17th ed.) Citation

Patil, Shivaprasad Gangadhar, et al. "A Novel 2-metagene Signature to Identify High-risk HNSCC Patients Amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT." Cancers 14, no. 12 (2022). https://doi.org/10.3390/cancers14123031.

MLA (9th ed.) Citation

Patil, Shivaprasad Gangadhar, et al. "A Novel 2-metagene Signature to Identify High-risk HNSCC Patients Amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT." Cancers, vol. 14, no. 12, 2022, https://doi.org/10.3390/cancers14123031.